21 Drug Discovery, Pharmaceuticals & Cannabis Testing Cannabinoid Distillation Systems for Industrial-Scale Production
The ProPass 600 series of cannabinoid distillation systems has been introduced by Pope Scientific. This industrial-grade module is a no-nonsense, high-performing workhorse, offering the best possible throughput to price ratio. The 600 series is equipped with Pope’s 6” stainless steel technology, which has been tried and tested to achieve extract feed rates of up to 10 kg/hr or more with exceptional yield, purity, and clarity in the end product.
The skid-mounted system comprises essential components for hassle-free, continuous operation round the clock. These components include upgraded liquid pumps, oversized vacuum pump, and a hygienic and ergonomic design that simplifies cleaning and maintenance. The entire system is constructed using 316L stainless steel for durability and high heat transfer rates, which translates into maximum efficiency and throughput. For safety, the system features a single point electrical hookup and internal wiring in compliance with NEC industrial standards. Like all equipment from Pope, each still is designed, manufactured, and tested in the USA and comes with a warranty. Furthermore, Pope’s renowned customer service is available for years after procurement.
Although the base ProPass 600 is an economical option that delivers robust performance right out of the box, Pope Scientific offers several equipment package options to cater to customers’ varying requirements, budgets, and preferences. These choices include increased levels of automation, data recording and management, and the option to include feed/receiver vessels. These single-stage modules are capable of performing both terpene stripping and cannabinoid distillation steps. For distilling large quantities of extract regularly, it is recommended to use multiple linked modules, typically two or more, depending on factors such as starting extract quality, pre-distillation process steps, and desired end product. After consultation, Pope Scientific can customise ProPass system proposals, and modules can be purchased together or added later as required.
With over 40 years of experience in providing distillation equipment, technology, and toll processing services to various industries worldwide, including pharma, foods, flavours, fragrances, oils, cosmetics, polymers, specialty chemicals, and the cannabis sector for more than seven years, Pope Scientific has established itself as a trustworthy and dependable partner for all your needs now and in the future.
More information online:
ilmt.co/PL/7NOj 59834pr@reply-direct.com
A Non-targeted Approach to Nitrosamine Screening down to PPB Levels
Ellutia, a leading provider of innovative analytical solutions, has recently launched the Automated Total Nitrosamine Analyser, a cutting-edge system that allows pharmaceutical companies and their suppliers to rapidly screen samples for total nitrosamine content down to ppb levels. The system is designed to supplement targeted nitrosamine testing, offering a faster and more comprehensive approach to identifying potential contaminants in pharmaceutical drugs. The need for this technology stems from the discovery of NDMA in Sartans in 2018, which led to increased concerns over nitrosamines in pharmaceutical drugs. Nitrosamines are potent carcinogens that can be formed unintentionally during the chemical synthesis of active pharmaceutical ingredients (APIs). As time has progressed, the focus has shifted to other Nitrosamine drug substance-related impurities (NDSRIs), which are often more complex and difficult to detect.
Targeted nitrosamine testing, which involves testing for specific nitrosamines, has been the most common analysis method to date. However, this approach only detects what the tester is looking for and is limited to known nitrosamines for which standards are available. The Automated Total Nitrosamine Analyser overcomes these limitations by screening for total nitrosamine content, including unexpected nitrosamines for which standards may not exist. The system offers a rapid and comprehensive approach to screening samples for nitrosamine content, allowing pharmaceutical companies to identify potential contaminants much more quicker. This enables them to focus their efforts using targeted analysis only on positive samples and avoid unexpected nitrosamine contamination from incoming ingredients.
More information online:
ilmt.co/PL/BKBb Investment in Lyobeads – A Massive Step Forward for Lyo R&D
Biopharma Group has taken its extensive experience within the freeze-drying industry to help increase lyophilisation productivity, reduce costs and reduce cycle times by increasing lyobead production capabilities. Biopharma Group’s lyobead generation line can create millions of lyobeads a month.
‘Lyobeads’ (lyophilised spheres) are a huge step forward in the lyophilisation fi eld and Biopharma Group has been at the forefront of its evolution. Lyobeads provide signifi cant benefi ts in addition to those of conventional ‘lyocakes’. Lyobeads are more adaptable to product container changes, which can reduce time for R&D investment. They are suitable for high throughput, giving the possibility to load more into your dryer. From a quality product perspective, a larger surface area means reconstitution time is typically very good. Finally, storage and handling is simplifi ed, since lyobeads can be stored in bulk prior to packaging, making storing and shipping far easier and safer for product viability.
Biopharma Group has invested heavily in lyobead technology and increased its production capabilities accordingly, which has proved to be of great value to R&D customers looking for fast delivery to market. With this move, millions of lyobeads can now be produced each month. Biopharma Group is proud to have designed and developed a ‘lyobeads generator’ which has the capacity to produce lyobeads based on the customer requirements.
Another benefi t to of this investment is that, in addition to its R&D services, Biopharma Group can offer a complete end-to-end lyobead production line, consisting of:
• Procurement and purchasing of reagents • Preparation and compounding • Generation of frozen beads • Freeze drying • Quality control • Picking-and-Placing • Packaging
This increases productivity, reduces costs in the areas of transportation and storage, increases product stability and offers fast reconstitution.
In addition to processing and production, Biopharma Group’s in-house team of scientists can support the design and development of both bespoke formulations and lyo processes. The goal is to create robust lyobeads, easy to reconstitute, that would also preserve the reagent activity.
Learn more about the contract R&D and manufacturing services Biopharma Group offers, or contact us with your requirements today.
More information online:
ilmt.co/PL/7Nz0 and
ilmt.co/PL/jx4o
59949pr@reply-direct.com
60023pr@reply-direct.com ADVERTORIAL
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
